The analysis of tumor cells or tumor cell products obtained from blood or other body fluids
(“liquid biopsy”[LB]) provides a broad range of opportunities in the field of oncology. Clinical …

In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …

The increase in recent scientific studies on cancer biomarkers has brought great new
insights into the field. Moreover, novel technological breakthroughs such as long read …

Simple Summary Apart from genetic changes, cancer is characterized by epigenetic
alterations, which indicate modifications in the DNA (such as DNA methylation) and histones …

Background Bacteria play a suspected role in the development of several cancer types, and
associations between the presence of particular bacteria and prostate cancer have been …

Liquid biopsy technologies have seen a significant improvement in the last decade, offering
the possibility of reliable analysis and diagnosis from several biological fluids. The use of …

Given the low specificity of the routinely used biomarker prostate-specific antigen, circulating
tumor cell (CTC) enumeration seems to be particularly useful in the monitoring of prostate …

Currently, sensitive and specific methods for the detection and prognosis of early stage PCa
are lacking. To establish the diagnosis and further identify an appropriate treatment strategy …

Simple Summary Prostate cancer is a heterogeneous disease and a major cause of cancer
deaths worldwide. The most widely used prostate cancer biomarker, prostate-specific …

Simple Summary Prostate cancer is a major cause of cancer-related death in men
worldwide. There is an urgent clinical need for improved prognostic biomarkers to better …